English

New data for OCD (Obsessive-compulsive disorder)

Report this content

SensoDetect has now received data from a new group of obsessive-compulsive disorder (OCD) that will be evaluated to supplement BERA 3.0 with additional report if possible.

SensoDetect BERA 3.0 will initially focus on ADHD according to previous plan and is supplemented with autism and schizophrenia. These tests will give the doctor a wider material to aid in their investigation and diagnosis. The data now collected concerns an additional group with Obsessive-Compulsive Disorder (OCD). These will be analyzed in the spring and if possible added to the BERA 3.0 tests.

As previously communicated, SensoDetect has strengthened the analysis and AI team to be able to intensify both the development of BERA 3.0 and new and exciting data to further create value for customers.

Obsessive Compulsive Disorder (OCD) has a lifetime prevalence of between 1-2.5% and affects women and men equally. People with untreated obsessive-compulsive disorder (OCD) often develop depression why early detection and treatment are central to the healthcare system.

"Could we offer an OCD test as a further part of the response to the psychiatry, it would be unique in its kind. It would increase the value for the psychiatry as OCD is a severe diagnosis that is diverse. A reliable and objective test does not exist as I know of since before and would therefore be a great addition to our BERA tests. However, it is too early to say when we can have such a test ready, but it is very interesting to get in solid data to work with. However, the focus is still on getting the BERA 3.0 on the market for ADHD tests and it goes according to plan.", says Johan Olson, CEO, SensoDetect AB (Publ.)

Johan Olson
CEO, SensoDetect Aktiebolag (publ)
Phone: +46 46-15 12 73
e-mail: jo@sensodetect.com

SensoDetect highlights through patented equipment brain stem responses to audio stimuli in order to provide health care clear anomalies and patterns for use primarily within psychiatry. The goal is to increase efficiency in Psychiatry and thus the benefits for health care, society, patients and relatives.

Our Mission
Improve the lives of people with mental illness
Our Vision
Making ABR profiling tests with SensoDetect technology an integral part of setting diagnosis for mental illness
Our Value Proposition:
SensoDetect provides a complete audiogram for the brainstem, helping health care professional to set psychiatric diagnoses objectively and
cost effectively. This unique offering improves patients’ quality of life and reduces the economic impact on the health care system and society

Tags:

ADHD autism schizophrenia psychiatrist Psychiatry mental illness dialysis mental OCD SensoDetect Brainsteam brain response state brainstem disorders cABR Brain stem ESRD end stage renal disease hemodialysis peritoneal brain disorder BERA Obsessive-compulsive

Subscribe

Documents & Links

Quotes

Could we offer an OCD test as a further part of the response to the psychiatry, it would be unique in its kind. It would increase the value for the psychiatry as OCD is a severe diagnosis that is diverse. A reliable and objective test does not exist as I know of since before and would therefore be a great addition to our BERA tests. However, it is too early to say when we can have such a test ready, but it is very interesting to get in solid data to work with. However, the focus is still on getting the BERA 3.0 on the market for ADHD tests and it goes according to plan.
CEO, Johan Olson, SensoDetect AB (publ.)